Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast, Q3'26

By Inderes11/5/2026, 9:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:01 - 05:04

Thank you and welcome, everyone, to the webcast for Ascelia Pharma's third quarter report for 2026. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma and recent key events, and then head into the portfolio update with an emphasis on the recent Type A meeting with the FDA. Before moving to Oncoral, financials, and priorities ahead after the presentation, we will open up for questions at Ascelia Pharma. We identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We are based in Malmö, Sweden, and are listed on Nasdaq Stockholm. We have two drugs in our pipeline. Orviglance is a diagnostic drug that has been submitted to the FDA to obtain approval in the US. We had a Type A meeting with the FDA in September to discuss the path to approval. Oncoral is a patented tablet formulation of irinotecan, with encouraging results in phase one and potential to treat a range of solid tumors. In early July, we received a Complete Response Letter from the FDA for our NDA submission for Orviglance. Later in July, we communicated organizational changes as well as the implementation of cost-reduction actions to improve our financial flexibility. In September, we announced the publication of our hepatic impairment clinical study in the peer-reviewed Journal of Magnetic Resonance Imaging. In September, we held the Type A meeting with the FDA to discuss the path to approval for Orviglance in the US. After the end of the quarter, we received the official minutes. The Complete Response Letter was a significant setback. We continue to believe in the value of Orviglance, how it can help patients, and its attractive commercial potential. Our strategic direction remains steady, and our strategic priorities are to continue the partnering process for Orviglance. We envisage a partnership to now include both development and commercialization. We are preparing for and meeting with the FDA to create alignment on an appropriate endpoint for a reread of the SPARKLE images that can lead to approval in the US, and we are also initiating a dialogue with the regulatory agencies in Europe to obtain their feedback on the approvability of Orviglance. Based on the existing data package that we have, we are in a cost-conscious manner also preparing Oncoral development and partnering dialogues. We will start the portfolio section of our presentation with Orviglance. So despite the setback with the Complete Response Letter, we continue to be very excited by Orviglance. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million addressable global market opportunity, and Orviglance is a first-in-class product to target this and has Orphan Drug Designation from the FDA. We have commercial-scale manufacturing in place, and we have strong data from nine clinical studies. We think Orviglance is an attractive asset, and we will work with a partner who will drive the final part of development and commercialization. Let's talk about how Orviglance can help patients. Cancer in the liver is a significant challenge in cancer care. Many different cancer types metastasize to the liver, meaning they start in another organ and spread to the liver. This accounts for approximately 90% of cancer in the liver in the US and Europe. The remaining 10% of cancer in the liver is when cancer originates in the liver. The liver is often the first organ where cancer spreads, and it is often also the cause of death. That is why cancer in the liver is a major issue in cancer care. Therefore, it is important to perform high-quality imaging to determine if the cancer has spread to the liver, how the cancer in the liver is responding to therapy, or for use in surgical planning. The best way to do this is with liver MRI, and today, it uses a gadolinium-based contrast agent. For most patients, this works well. However, patients with severe renal disease are at risk for a potentially fatal gadolinium-induced side effect known as nephrogenic systemic fibrosis. Regulatory agencies have requested a black box warning on gadolinium products because of this risk. It is exactly these patients that we aim to help. Orviglance provides high-quality imaging, and because it is based on manganese, there are none of the gadolinium-associated risks. This unmet medical need translates into a global addressable market opportunity of $800 million on an annual basis. The US market accounts for almost half of this total. Therefore, the US market has been prioritized by Ascelia Pharma. Ascelia Pharma will work with partners to drive the commercialization of Orviglance. And now, I will hand over to Andreas to discuss the path for approval.

Andreas Norlin
05:07 - 14:18

Thank you. Magnus. So the Type A meeting with the FDA was an important and constructive step forward for the Orviglance program. While the FDA continues to require additional clinical evidence for approval, the meeting substantially reduced uncertainty around both the product quality and clinical components of the Complete Response Letter. Several important areas of alignment were established during the discussions, and the FDA acknowledged the significant unmet medical need in patients with severe renal impairment, which is a patient population with limited access to contrast-enhanced MRI. Today, the agency also acknowledged the favorable safety profile of Orviglance and its technical performance as a liver-specific T1-enhancing contrast agent. And importantly, the FDA confirmed that the existing clinical data package retains value and may contribute as supportive evidence in a future submission. On the product quality side, we reached alignment on the proposed strategy to address the observations raised in the CRL, and this is important because it removes a significant area of uncertainty, and FDA expectations are now understood and the implementation activities have already started. Finally, the meeting clarified that the key remaining regulatory question relates to the demonstration of clinical utility. And this was the most important outcome of the meeting regarding the Complete Response Letter. The FDA's recommendation was to conduct a new clinical study with new patients. During the Type A meeting, FDA confirmed that this remains one possible route of approval. However, the agency also acknowledged an alternative approach. FDA indicated that additional clinical evidence could potentially be generated through a new evaluation of the existing SPARKLE image database using a different primary endpoint than originally used. We view this as a significant and encouraging development. Rather than having a single path forward based on a completely new clinical study, there is now the possibility of leveraging the substantial clinical data that have already been generated. Additional work is still required, and our immediate focus is to identify endpoints that appropriately address the FDA's concerns and demonstrate clinical utility. And before initiating any image reading process, we intend to align with the FDA on the selected endpoint through a Type A meeting. So having discussed the regulatory progress for Orviglance, I would now like to spend a few minutes on our second oncology asset, Oncoral. So while the company's immediate focus remains advancing. Orviglance. Towards approval and partnering, Oncoral continues to represent an important long-term value opportunity. Over the last decade or so, oncology has seen tremendous progress through targeted therapies and immunotherapies. Despite these advances, chemotherapy continues to be used in the majority of patients with solid tumors and remains a cornerstone of cancer treatment. At the same time, patients are living longer, making treatment burden, cumulative toxicity, and quality of life increasingly important considerations. Regulators, clinicians, and oncology societies are paying greater attention to these aspects when assessing treatment value. This creates a significant opportunity for treatment approaches that preserve anti-tumor efficacy while reducing toxicity and improving quality of life. We believe this trend is highly relevant to Oncoral and forms part of the rationale behind our development strategy. Oncoral is designed to fundamentally change how irinotecan is delivered. Conventional irinotecan is administered intravenously at relatively high doses every few weeks, and this results in high peak drug concentrations that are frequently associated with toxicities, followed by prolonged periods with minimal exposure. Oncoral enables a very different dosing strategy through daily oral administration. The goal is to create a more sustained exposure profile over time. And this approach, sometimes referred to as metronomic dosing, has the potential to improve tolerability while maintaining anti-tumor activity. Sustained exposure may also allow irinotecan to affect not only tumor cells directly, but also biological processes within the tumor microenvironment that are difficult to target with conventional intermittent dosing. So in simple terms, we believe Oncoral may allow us to use a proven chemotherapy in a smarter and potentially more effective way. This slide explains why we believe Oncoral is more than simply an oral formulation of Irinotecan. Many groups have attempted oral irinotecan development over the years. The challenge has been achieving sufficiently predictable pharmacokinetics and bioavailability to support reliable chronic dosing. The proprietary Oncoral tablet technology addresses this challenge and enables daily administration with a pharmacokinetic profile suitable for metronomic treatment. Our Phase 1 studies provided encouraging evidence supporting this concept, and we observed predictable drug exposure, favorable tolerability, and stable disease in a number of heavily pretreated patients. Taken together, these findings support the feasibility of transforming irinotecan from an intermittent infusion therapy into a continuous metronomic treatment strategy. That is why we like to describe Oncoral as a dosing platform rather than a simple reformulation. So Oncoral is more than just another dosage form of irinotecan, and this distinction is important. Oncoral differs from conventional irinotecan in several ways. First, the pharmacology is different because patients receive continuous low-dose exposure rather than intermittent high-dose treatment, as I just described. And second, the biology may be different. Metronomic chemotherapy has been associated with anti-angiogenic and immunomodulatory effects that extend beyond direct tumor killing. Tumor cell killing. And third, the treatment feasibility is different. Daily chronic irinotecan treatment is simply not practical. Using intravenous administration. And finally, the clinical opportunities may be different. This approach could potentially be applicable in maintenance settings and combination regimens where conventional irinotecan is difficult to use. For these reasons, we believe Oncoral should be viewed as a platform, enabling a distinct therapeutic approach rather than merely an oral substitute for existing irinotecan products. Our current development focus is gastric cancer, and this indication represents a significant unmet medical need, and it's an area where irinotecan already has established clinical relevance. An important part of the rationale comes from preclinical data demonstrating synergy between irinotecan and Lonsurf, and these studies suggest greater anti-tumor activity when the two agents are combined than when either is used alone. So this combination is particularly attractive because both treatments are administered orally, creating the possibility of a fully oral treatment regimen. While gastric cancer is our lead indication, we view it as a beginning rather than the end of the opportunity. Irinotecan has established anti-tumor activity across multiple solid tumors and remains included in treatment guidelines for several major cancer types. The broader vision for Oncoral is therefore to apply the daily oral dosing concept wherever irinotecan biology and clinical experience support such an approach, and as shown on this slide, several of these indications represent very substantial patient populations and commercial opportunities. This gives Oncoral the potential to evolve from a single product opportunity into a broader platform, capable of generating value across multiple cancers. In summary, we are not simply developing an oral Irinotecan product. We are developing a new way of using Irinotecan with the potential to improve patient experience while preserving and potentially enhancing therapeutic benefits. So with that, I will hand back to Magnus to discuss financials and outlook.

Magnus Corfitzen
14:19 - 15:49

Thank you, Andreas. So, in Q3, our operating loss was 10 million Swedish kronor. As you can see, this is lower than previous quarters, which relates to the end of the NDA review process and our cost reduction initiatives. That leaves us with 28 million SEK at the end of Q3. With our cost projections, this provides cash runway into Q2 next year. I will end our presentation by reiterating our key priorities and milestones. We continue the partnering process for Orviglance. The partnership will now include both further development and full commercialization. We are preparing a meeting with the FDA to create alignment on an appropriate endpoint for the reread of the SPARKLE images that can lead to approval in the US. As Andreas went through, we are also preparing dialogue with regulatory agencies in Europe to obtain their feedback on the approvability of Orviglance based on the existing data package. As mentioned, in a cost-conscious manner, we are also preparing Oncoral development and having partnering dialogues on that. We are not where we hope to be at this point. We have a clear plan, we have clear inflection points, and there continues to be an attractive opportunity for the drugs in our pipeline, and we're committed to bringing them to the patients who need them. Thank you for listening to our Q3 update. The operator would now like to open the floor for questions.

Operator
15:51 - 16:10

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Maria Karlsson Osipova from DNB Carnegie. Please go ahead.

Maria Karlsson Osipova
16:12 - 16:31

Hi, Magnus and Andreas, thank you for taking my question. So we've only recently spoken about this, but yet again, a little on the FDA process. We have mentioned a Type C meeting as soon as possible. When would you expect to provide an update for us on your plan forward? And have you had any follow-up interaction with the FDA? On the topic?

Magnus Corfitzen
16:34 - 16:34

You want to start with that?

Andreas Norlin
16:35 - 17:07

So yes. Thank you. It is a good question. Well, we will come back with timelines when we have them more specified. But we are prioritizing this. And we are of course aware of that. We need to address this as soon as possible. So the process is ongoing. And we are planning for the meeting with the FDA, and hopefully, sometime in early next year, we can say more about this. Yeah. So we are.

Magnus Corfitzen
17:07 - 17:20

We are aware that this is the top priority, and we are also being conscious of our cash runway. I think that sets the priorities and timelines in a reasonable perspective.

Maria Karlsson Osipova
17:23 - 17:36

All right. Thank you. We always look to touch upon Europe, specifically regarding which markets are the initial priority for you. And yet again, their follow-up on the expected timing.

Magnus Corfitzen
17:38 - 18:13

I believe the backdrop of this is that we have a strong, compelling data package. We were surprised that we did not receive approval in the US. But it is what it is. Now we focus on how we get approval in the US. Having said that, we have this comprehensive data and manufacturing process, which may be sufficient for getting approval in Europe because they may have a different regulatory perspective on the data. We will definitely pursue that. So that is why we are prioritizing this activity as well.

Maria Karlsson Osipova
18:18 - 18:20

All right. Thank you. That will be all for me.

Magnus Corfitzen
18:21 - 18:22

Thank you, Maria.

Operator
18:23 - 18:29

The next question comes from Georg Bjork from ABG Sundal Collier. Please go ahead.

Georg Bjork
18:31 - 19:17

Hi, this is Georg from ABG. I have two questions, please. So firstly, could you elaborate on whether the FDA has suggested a specific new primary endpoint for SPARKLE. Could you provide more clarity on the data there, please? And then secondly, of course, subject to what happens to Orviglance, which I of course appreciate that you currently do not know. I am wondering if you could elaborate on what is your current base case development path for Oncoral in gastric cancer? Perhaps both in a positive and negative scenario for Orviglance, please. Thank you.

Andreas Norlin
19:19 - 20:59

Regarding your first question about what a new endpoint could be, the FDA has not been specific beyond their initial comments. I think it is always the sponsor's responsibility to develop their development program, but I think you can look at what others have done before. That may, of course, give you some indication of what the FDA would consider useful endpoints. The important thing is that we can address the main question, which is demonstration of clinical utility. And in my personal perspective, in this area of imaging products, there are different ways to achieve this. And I think also the history shows that when looking at different contrast agents and what their indication and what the primary endpoints in their pivotal studies have been. It is important that we find something that meets those requirements, but they should also be feasible from an operational point of view. It also has to be statistically robust and so on. So there is some homework for us to do, but we are very hopeful that we will be able to find something. The work is progressing finally. So that was the first question, a long answer. Do you want to say something about it?

Magnus Corfitzen
21:00 - 21:00

Yeah.

Andreas Norlin
21:00 - 21:01

Oncoral.

Magnus Corfitzen
21:01 - 21:42

Yeah. No, I think as Andreas also shared, I appreciate the question. As you know, we have a plan. And we have a clinical collaboration, and Taiho Oncology has been very patient. And we appreciate that very much. As I said, there are many different opportunities with this agent. So I think the important thing is to prioritize and identify where we can have the biggest impact. So I think that is the important element that we continue to monitor, also looking at what is happening in the oncology space. I don't know if you want to comment on that.

Andreas Norlin
21:42 - 22:07

No, I think that's right, but maybe just a general comment and I want to pick up on what you ended with. The oncology space is continuously evolving. It is a very important field, but there are also a lot of things going on. So it is important that you continuously monitor that and adjust the strategies accordingly.

Magnus Corfitzen
22:07 - 22:37

So what we see is some spectacular results from a number of products, such as ADCs or others, which is great for humanity and cancer care. But as Andreas also mentioned, a majority of patients today are receiving chemotherapy. And we think we can with Oncoral have a very good product for some of these patients. And that is our focus. Not going head-to-head with the ADCs. Yeah.

Georg Bjork
22:40 - 22:41

Thank you.

Magnus Corfitzen
22:42 - 22:43

Yeah. Thanks.

Operator
22:45 - 22:57

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Frederick Thaw from Redeye. Please go ahead.

Georg Bjork
22:59 - 23:36

Hello. And thank you. Most questions have been answered, but I just wondered if you mentioned in the intro there that the new study with the additions, as you have said, also opens up the potential to utilize SPARKLE; can you maybe discuss a bit more how this was framed? I mean, was it framed exactly like this, that there is an alternative? What do you think will be enough for them to be convinced that this alternative approach could be sufficient? If you define the endpoint, or is it? What do you think we need to see?

Andreas Norlin
23:39 - 24:39

I think it's fair to say that the FDA is open to this, and I think you can say that. Well, then, it is well known, just by looking at the history and for other drugs, that re-reads of certain types or re-evaluations have been accepted before. So along those lines, the FDA is open to considering this, although the challenge with the FDA was that we made the same type of evaluation in the reread as we did in the first read. So that is the sticking point, so to say. So, both based on history and, of course, on the dialogue we had in the meeting. The FDA is open to this and is quite keen on discussing how we can bring this forward.

Magnus Corfitzen
24:40 - 25:31

And another way to look at it. I mean, the FDA wants to ensure that patients in the US get access to safe and effective medicine. And they also, as we point out, acknowledge and reiterate the unmet medical need that we address with Orviglance. They also provided feedback on the safety profile, which is very encouraging, and on the technical performance. So what they want is the data that will make them able to conclude that Orviglance should be approved. And those are the different routes that they see could be sufficient for approving the product. So, I think it's very much in recognition of the unmet need and you could say all the existing data. But they just want a bit more.

Georg Bjork
25:32 - 25:47

Got it. And at the Type A meeting, what would be the best outcome? How strong of an endorsement could they give you? I mean, obviously they cannot promise anything, but can they say they approve this trial? Yeah.

Andreas Norlin
25:48 - 26:31

We would expect them to agree on the strategy and the plan for how we. We plan to conduct this new evaluation. Otherwise, there is no meaning in having the meeting if we cannot reach that agreement. But of course they will not say that now we can approve it because we still need to generate the data and they will make a new decision based on that. But having an alignment on how to do it and what the measurements are, and what the statistical analytical approach is, that kind of agreement we would expect from a Type C meeting.

Magnus Corfitzen
26:31 - 26:38

Yeah. So, a very specific endpoint. Yes. That is correct. We know this is how we are going to do it. That should be the outcome of the meeting.

Georg Bjork
26:40 - 26:42

Got it. Thank you very much.

Magnus Corfitzen
26:43 - 26:43

Thanks.

Operator
26:46 - 26:53

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Magnus Corfitzen
26:55 - 27:13

Yeah. So, thank you everyone for joining. There were no written questions. So, I think we also got good coverage from the questions that were made here in the Q&A session. So, thank you very much. And we look forward to updating you on the progress of Orviglance and Oncoral.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…